Gold(III) porphyrin 1a inhibited nasopharyngeal carcinoma metastasis in vivo and inhibited cell migration and invasion in vitro

Cancer Letters

Volumn 294, Issue 2, 2010, Pages 159-166

  Lum, Ching Tung ^a   Liu, Xiong ^a,b   Sun, Raymond Wai Yin ^a   Li, Xiang Ping ^b   Peng, Ying ^c   He, Ming Liang ^d   Kung, Hsiang Fu ^c,d   Che, Chi Ming ^a   Lin, Marie C M ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b FIRST MILITARY MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cell migration; Gold(III) porphyrin 1a; Invasion; Metastasis; Nasopharyngeal carcinoma (NPC)

Indexed keywords

ACYLGLYCEROL LIPASE; TETRAPHENYLPORPHYRIN DERIVATIVE; TETRAPHENYLPORPHYRIN GOLD; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR NECROSIS;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; GENE EXPRESSION PROFILING; GOLD; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MALE; METALLOPORPHYRINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MONOACYLGLYCEROL LIPASES; NASOPHARYNGEAL NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; RATTUS;

EID: 77953363272     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.033     Document Type: Article

References (32)

1. Tao Q., Chan A.T. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev. Mol. Med. 2007, 9:1-24.
2. Ma B.B., Hui E.P., Chan A.T. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci. 2008, 99:1311-1318.
3. Cagnoli M., Alama A., Barbieri F., Novelli F., Bruzzo C., Sparatore F. Synthesis and biological activity of gold and tin compounds in ovarian cancer cells. Anticancer Drugs 1998, 9:603-610.
4. Coronnello M., Mini E., Caciagli B., Cinellu M.A., Bindoli A., Gabbiani C., Messori L. Mechanisms of cytotoxicity of selected organogold(III) compounds. J. Med. Chem. 2005, 48:6761-6765.
5. Gabbiani C., Casini A., Messori L., Guerri A., Cinellu M.A., Minghetti G., Corsini M., Rosani C., Zanello P., Arca M. Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties. Inorg. Chem. 2008, 47:2368-2379.
6. n+ compounds: synthesis and cytotoxic properties. Chemistry 2006, 12:5253-5266.
7. Marcon G., Carotti S., Coronnello M., Messori L., Mini E., Orioli P., Mazzei T., Cinellu M.A., Minghetti G. Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties. J. Med. Chem. 2002, 45:1672-1677.
8. Milacic V., Chen D., Ronconi L., Landis-Piwowar K.R., Fregona D., Dou Q.P. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res. 2006, 66:10478-10486.
9. Shaw C.F. Gold-based therapeutic agents. Chem. Rev. 1999, 99:2589-2600.
10. Sun R.W., Ma D.L., Wong E.L., Che C.M. Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans. 2007, 43:4884-4892.
11. Tiekink E.R. Gold derivatives for the treatment of cancer. Crit. Rev. Oncol. Hematol. 2002, 42:225-248.
12. Che C.M., Sun R.W., Yu W.Y., Ko C.B., Zhu N., Sun H. Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. Chem. Commun. 2003, 14:1718-1719.
13. Lum C.T., Yang Z.F., Li H.Y., Sun R.W., Fan S.T., Poon R.T., Lin M.C., Che C.M., Kung H.F. Gold(III) compound is a novel chemo-cytotoxic agent for hepatocellular carcinoma (HCC). Int. J. Cancer 2006, 118:1527-1538.
14. To Y.F., Sun R.W., Chen Y., Chan V.S., Yu W.Y., Tam P.K., Che C.M., Lin C.L. Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo. Int. J. Cancer 2009, 124:1971-1979.
15. Li W., Xie Y., Sun R.W., Liu Q., Young J., Yu W.Y., Che C.M., Tam P.K., Ren Y. Inhibition of Akt sensitizes neuroblastoma cells to gold(III) porphyrin 1a, a novel antitumour drug induced apoptosis and growth inhibition. Br. J. Cancer 2009, 101:342-349.
16. Tu S., Sun R.W., Lin M.C., Cui J.T., Zou B., Gu Q., Kung H.F., Che C.M., Wong B.C. Gold(III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer. Cancer 2009, 115:4456-4469.
17. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 2002, 99:10819-10824.
18. Nithipatikom K., Endsley M.P., Isbell M.A., Falck J.R., Iwamoto Y., Hillard C.J., Campbell W.B. 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004, 64:8826-8830.
19. Cheung S.T., Huang D.P., Hui A.B., Lo K.W., Ko C.W., Tsang Y.S., Wong N., Whitney B.M., Lee J.C. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int. J. Cancer 1999, 83:121-126.
20. Weitman S., Langevin A.M., Berkow R.L., Thomas P.J., Hurwitz C.A., Kraft A.S., Dubowy R.L., Smith D.L., Bernstein M. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin. Cancer Res. 1999, 5:2344-2348.
21. Li X.P., Li C.Y., Li X., Ding Y., Chan L.L., Yang P.H., Li G., Liu X., Lin J.S., Wang J., He M., Kung H.F., Lin M.C., Pen Y. Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus-mediated expression of human endostatin. Mol. Cancer Ther. 2006, 5:1290-1298.
22. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., Meli S., Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 1992, 84:1875-1887.
23. Kopf-Maier P. Complexes of metals other than platinum as antitumour agents. Eur. J. Clin. Pharmacol. 1994, 47:1-16.
24. Tao Q., Chan A.T. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev. Mol. Med. 2007, 9:1-24.
25. Ma B.B., Chan A.T. Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Rev. Anticancer Ther. 2006, 6:383-394.
26. Wang X X., Masters J.R., Wong Y.C., Lo A.K., Tsao S.W. Mechanism of differential sensitivity to cisplatin in nasopharyngeal. Anticancer Res. 2001, 21:403-408.
27. Wang Y., He Q.Y., Tsao S.W., Cheung Y.H., Wong A., Chiu J.F. Cytokeratin 8 silencing in human nasopharyngeal carcinoma cells leads to cisplatin sensitization. Cancer Lett. 2008, 265:188-196.
28. Raz A., Ben-Ze'ev A. Cell-contact and architecture of malignant cells and their relationship to metastasis. Cancer Metastasis Rev. 1987, 6:3-21.
29. Cheng J.C., Chou C.H., Kuo M.L., Hsieh C.Y. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 2006, 25:7009-7018.
30. Gjerstorff M.F., Benoit V.M., Laenkholm A.V., Nielsen O., Johansen L.E., Ditzel H.J. Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelial. Int. J. Oncol. 2006, 28:1327-1335.
31. Rudolph M.I., Boza Y., Yefi R., Luza S., Andrews E., Penissi A., Garrido P., Rojas I.G. The influence of mast cell mediators on migration of SW756 cervical carcinoma cells. J. Pharmacol. Sci. 2008, 106:208-218.
32. Wang Y., He Q.Y., Sun R.W., Che C.M., Chiu J.F. GoldIII porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res. 2005, 65:11553-11564.